4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

SALT LAKE CITY, Nov. 15, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 at 4:00 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements. A live webcast of the company's prese

SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study underway after database was locked in September and now seeking publication of results in connection wit

SALT LAKE CITY, Oct. 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

SALT LAKE CITY, Sept. 4, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. Wainwright Global Investment Conference on Wednesday, September 11, 2024 at 10:00 a.m. ET. Zhenya Lindgardt, President and CEO, will provide a company update and discuss Sera's latest achievements. A live webcast of the company's presentation as well as a webcast replay will be availabl

SALT LAKE CITY, Aug. 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its management team will participate in the following upcoming investor conference:  UBS Genomic Medicine Summit, August 13-14. President and Chief Executive Officer, Zhenya Lindgardt, will participate in a panel discussion: Future of Genetic Testing – Babies and Beyond, on August 14 at 8:00 a.m. Pacific Time/11:00 a.m. Eas

SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights: Publication of positive AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls) results in international peer-reviewed journal, Diagnostics, with coverage on front page of publication.Data analysis fo

SALT LAKE CITY, July 25, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2024 financial results on Wednesday, August 7, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics SALT LAKE CITY, July 9, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication in Diagnostics, an international, peer-reviewed, open access journal on medical diagnosis, of the top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware.

SALT LAKE CITY, July 1, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that as a result of the annual Russell Reconstitution being finalized on June 28, 2024, the Company has been added to the Russell Small-Cap 2000 and Russell 3000 indexes effective with the opening of equity markets today. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th,

SALT LAKE CITY, May 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes as part of the Russell indexes annual reconstitution. "We are pleased to be included in the preliminary list of the Russell 3000 Index, as it marks another step forward for Sera during a year in which we expect to achieve severa

Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00

Cowen resumed coverage of Sera Prognostics with a rating of Outperform

William Blair initiated coverage of Sera Prognostics with a rating of Outperform

Cowen initiated coverage of Sera Prognostics with a rating of Outperform

Citigroup initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $18.00

SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study underway after database was locked in September and now seeking publication of results in connection wit

SALT LAKE CITY, Oct. 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights: Publication of positive AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls) results in international peer-reviewed journal, Diagnostics, with coverage on front page of publication.Data analysis fo

SALT LAKE CITY, July 25, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2024 financial results on Wednesday, August 7, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2024 ended March 31, 2024. Recent Highlights: Submitted manuscript of PRIME study interim analysis results for peer-reviewed publication.Shipped first ambient whole blood collection kits, which we believe is critical to facilitating new commercial opportunities and is expected to yield s

SALT LAKE CITY, April 29, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2024 financial results on Wednesday, May 8, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

SALT LAKE CITY, March 20, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights: Announced that the Data Safety Monitoring Board (DSMB) overseeing Sera's pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enrollment due to

SALT LAKE CITY, March 4, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, March 20, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

SALT LAKE CITY, Aug. 9, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2023 ended June 30, 2023. Recent Highlights: Announced leadership changes and commercial actions in May 2023 to optimize business for market success toward accelerating test adoption and revenue including aligning management team for new refined commercial focus on institutions.Appoint

SALT LAKE CITY, July 31, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2023 financial results on Wednesday, August 9, 2023, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the Company. Dr. Critchfield plans to step down from his executive role effective June 8, 2023, to pursue other activities. Zhenya Lindgardt, a member of the Company's Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President. Kim Kamdar, Ph.D., a member of the

- Accomplished business and health services leader joins Sera in its quest to improve pregnancy outcomes of mothers and babies - SALT LAKE CITY, April 12, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Dr. Jane F. Barlow has joined the Sera Board of Directors. "We are very excited to have Dr. Jane Barlow join Sera's talented board," said Gregory C. Critchfield, CEO and Chairman of Sera Prognos

SALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Sandra A. J. Lawrence has joined the Sera Board of Directors. "We are very excited to have Sandra Lawrence join the Sera board," said Gregory C. Critchfield, CEO and Chairman of Sera Prognostics. "Sandra brings to Sera her broad and profound leadership experience having served on multiple public and private boards across

SALT LAKE CITY, Nov. 8, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Zhenya Lindgardt has joined the Sera Board of Directors. "We are thrilled to have Zhenya Lindgardt bring her vast and highly relevant experience to our board to improve the well-being of mothers and babies," said Gregory C. Critchfield, CEO and Chairman of Sera Prognostics, Inc.  "Zhenya possesses the rare combination of d

SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Woodrow Myers, M.D., M.B.A., joins Sera as an advisor focusing on public and political affairs. Dr. Myers will work on a multi-disciplinary effort to execute a national and state-specific political and public affairs strategy focused on Health Equity and Disparities related to pregnancy and parturition, further emphasizing the Company's efforts to help address the healthcare disparities that disproportionately affect underserved communiti

Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy SALT LAKE CITY, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Dr. Paul Kearney to the position of Chief Data Officer, effective October 1, 2021. As the chief data/analytics officer, Dr. Kearney will have responsibility to help direct, manage and analyze the large and growing data sets of Sera, both scientific and busin

SALT LAKE CITY, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Dr. Michael R. Foley has been appointed to the position of Chief Medical Officer beginning in January 2022. Dr. Foley will lead all medical activities for Sera as the company executes its vision to be the Pregnancy Company™. He joins a group of talented clinical operations and medical professionals who support Sera's collaborations with research teams across the globe. "We are honored to have Dr. Foley bring his extensive Materna

Trial Conducted At ChristianaCare In Wilmington, Delaware, Focused On Improving Maternal And Neonatal Health

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that as a result of the annual Russell Reconstitution being finalized on June 28, 2024, the Company has been added to the Russell Small-Cap 2000 and Russell 3000 indexes effective with the opening of equity markets today.

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes as part of the Russell indexes annual reconstitution.

Sera Prognostics (NASDAQ:SERA) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 26.47 percent increase over losses of $(0.34) per share from the same period last year.

Shares of JPMorgan Chase & Co. (NYSE:JPM) fell sharply during Friday’s session following first-quarter earnings. Net revenue (managed) of $42.5 billion (+8% Y/Y), beating the consensus of $41.8 billion. Excluding an item resulted in an increase of $550 million (after tax) to reported net income from $13.4 billion to $14.0 billion and an increase of $0.19 per share to reported EPS from $4.44 to $4.63. EPS was $4.44, beating the consensus of $4.15. JPMorgan Chase shares dipped 5.1% to $185.49 on Friday. Here are some other stocks moving in today's mid-day session. Gainers PaxMedica, Inc. (NASDAQ:PXMD) jumped 143% to $1.0101 after the company announced the completed execution of its thr

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. Shares of Aehr Test Systems (NASDAQ:AEHR) fell sharply during Monday’s session after the company reported preliminary third-quarter and FY24 adjusted EPS and revenue results below estimates. Aehr reported preliminary third-quarter revenue of $7.6 million and adjusted loss of 3 cents to 4 cents per share, according to data from Benzinga Pro. Aehr Test System shares tumbled 18.1% to $12.01 on Monday. Here are some other big stocks recording losses in today’s session. Vimeo, Inc. (NASDAQ:VMEO) shares declined 26% to $3.9800. Invivyd, Inc. (NASDAQ:IVVD) fell 16.7% to $3.63. Canopy Growth Corporation (

Sera Prognostics (NASDAQ:SERA) reported its Q4 earnings results on Wednesday, March 20, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Sera Prognostics beat estimated earnings by 4.0%, reporting an EPS of $-0.25 versus an estimate of $-0.26. Revenue was down $24 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.11 which was followed by a 8.0% drop in the share price the next day. Here's a look at Sera Prognostics's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.34 -0.36 -0.38 -0.37 EPS Actual -0.23 -0.34 -0.34 -0.31 Revenue Estimate 90K 120K 80K 140K Reve

Sera Prognostics (NASDAQ:SERA) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. The company reported quarterly sales of $41.000 thousand which missed the analyst consensus estimate of $50.000 thousand by 18.00 percent. This is a 36.92 percent decrease over sales of $65.000 thousand the same period last year.

Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million. • Fanhua (NASDAQ:FANH) is estimated to report earnings for its fourth quarter. • Mogo (NASDAQ:MOGO) is likely to report quarterly loss at $0.09 per share on revenue of $12.14 million. • Ollie's Bargain Outlet (NASDAQ:OLLI) is projected to report quarterly earnings at $1.15 per share on revenue of $641.29 million. • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $271.46 million. • Boyd Gaming (NYSE:BYD) is estimated to report quarterly earnings at $1.49 per share on revenu

Sera Prognostics (NASDAQ:SERA) is set to give its latest quarterly earnings report on Wednesday, 2024-03-20. Here's what investors need to know before the announcement. Analysts estimate that Sera Prognostics will report an earnings per share (EPS) of $-0.26. Sera Prognostics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company beat EPS by $0.11, which was followed by a 7.61% d